Page 125 - VIII REPORT HS (2013-2014)
P. 125
( 114 ) APPENDICE 2- PUBBLICAZIONI SU RIVISTE INDICIZZATE SU PUBMED
Med. 2013 Sep;107(9):1417-22.
13. Ravera M, Noberasco G, Signori A, Re M, Filippi A, Cannavò R, Weiss U, Cricelli C, Defer-
rari G, Paoletti E. Left-ventricular hypertrophy and renal outcome in hypertensive patients
in primary-care. Am J Hypertens. 2013 May;26(5):700-7.
14. Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, Bianchini E, Medea
G, Cricelli C, Caputi AP, Mazzaglia G. Epidemiology of gout and hyperuricaemia in Italy
during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2013
May;72(5):694-700.
15. Gini R, Francesconi, Mazzaglia G, Cricelli I, Pasqua A, Gallina P, Brugaletta S, Donato D,
Donatini A, Marini A, Zocchetti C, Cricelli C, Damiani G, Bellentani M, Sturkenboom MC,
Schuemie MJ. Chronic disease prevalence from Italian administrative databases in the
VALORE project: a validation through comparison of population estimates with general
practice databases and national survey. BMC Public Health. 2013 Jan 9;13:15.
16. Schuemie MJ, Coloma PM, Straatman H, Herings RM, Trifirò G, Matthews JN,Prieto-Me-
rino D, Molokhia M, Pedersen L, Gini R, Innocenti F, Mazzaglia G,Picelli G, Scotti L, van
der Lei J, Sturkenboom MC. Using Electronic Health Care Records for Drug Safety Signal
Detection: A Comparative Evaluation of Statistical Methods. Med Care. 2012 Aug 26.
17. Valkhoff VE, van Soest EM, Masclee GM, de Bie S, Mazzaglia G, Molokhia M,Kuipers
EJ, Sturkenboom MC. Prescription of nonselective NSAIDs, coxibs and gastroprotective
agents in the era of rofecoxib withdrawal - a 617 400-patient study. Aliment Pharmacol
Ther. 2012 Aug 28.
18. Aguglia E, Ravasio R, Simonetti M, Pecchioli S, Mazzoleni F. Use and treatment modalities
for SSRI and SNRI antidepressants in Italy during the period 2003-2009. Curr Med Res
Opin. 2012 Jul 19.
19. Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M,Bianchini E, Medea
G, Cricelli C, Caputi AP, Mazzaglia G. Epidemiology of gout and hyperuricaemia in Italy
during the years 2005-2009: a nationwide population-based study.Ann Rheum Dis. 2012
Jun 26.
20. Valkhoff VE, van Soest EM, Mazzaglia G, Molokhia M, Schade R, Trifiro G,Goldstein JL,
Hernandez-Diaz S, Kuipers EJ, Sturkenboom MC. Adherence to gastroprotection during
cyclooxygenase 2 inhibitor treatment and therisk of upper gastrointestinal tract events: A
population-based study. Arthritis Rheum. 2012 Aug;64(8):2792-802.
21. Coloma PM, Trifirò G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Picelli
G, Corrao G, Pedersen L, van der Lei J, Sturkenboom M; EU-ADR Consortium. Electronic
healthcare databases for active drug safety surveillance: is there enough leverage? Phar-
macoepidemiol Drug Saf. 2012 Jun;21(6):611-21.
22. Trifirò G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, Herings R,
de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini
R, Sturkenboom MC. Risk of cardiac valve regurgitation with dopamine agonist use in
Parkinson’s disease and hyperprolactinaemia: a multi-country, nested case-control study.
Drug Saf. 2012 Feb 1;35(2):159-71.
23. Mokhles MM, Trifirò G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM,Mazzaglia
G, Herings R, Luise Cd, Ross D, Brusselle G, Colao A, Haverkamp W,Schade R, Camp Gv,
Zanettini R, Sturkenboom MC. The risk of new onset heart failure associated with dopa-
mine agonist use in Parkinson’s disease. PharmacolRes. 2012 Mar;65(3):358-64.
24. Lapi F, Simonetti M, Michieli R, Pasqua A, Brandi ML, Frediani B, Cricelli C, Mazzaglia G.
Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary
care. Bone. 2012 Jan;50(1):85-90.
Med. 2013 Sep;107(9):1417-22.
13. Ravera M, Noberasco G, Signori A, Re M, Filippi A, Cannavò R, Weiss U, Cricelli C, Defer-
rari G, Paoletti E. Left-ventricular hypertrophy and renal outcome in hypertensive patients
in primary-care. Am J Hypertens. 2013 May;26(5):700-7.
14. Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, Bianchini E, Medea
G, Cricelli C, Caputi AP, Mazzaglia G. Epidemiology of gout and hyperuricaemia in Italy
during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2013
May;72(5):694-700.
15. Gini R, Francesconi, Mazzaglia G, Cricelli I, Pasqua A, Gallina P, Brugaletta S, Donato D,
Donatini A, Marini A, Zocchetti C, Cricelli C, Damiani G, Bellentani M, Sturkenboom MC,
Schuemie MJ. Chronic disease prevalence from Italian administrative databases in the
VALORE project: a validation through comparison of population estimates with general
practice databases and national survey. BMC Public Health. 2013 Jan 9;13:15.
16. Schuemie MJ, Coloma PM, Straatman H, Herings RM, Trifirò G, Matthews JN,Prieto-Me-
rino D, Molokhia M, Pedersen L, Gini R, Innocenti F, Mazzaglia G,Picelli G, Scotti L, van
der Lei J, Sturkenboom MC. Using Electronic Health Care Records for Drug Safety Signal
Detection: A Comparative Evaluation of Statistical Methods. Med Care. 2012 Aug 26.
17. Valkhoff VE, van Soest EM, Masclee GM, de Bie S, Mazzaglia G, Molokhia M,Kuipers
EJ, Sturkenboom MC. Prescription of nonselective NSAIDs, coxibs and gastroprotective
agents in the era of rofecoxib withdrawal - a 617 400-patient study. Aliment Pharmacol
Ther. 2012 Aug 28.
18. Aguglia E, Ravasio R, Simonetti M, Pecchioli S, Mazzoleni F. Use and treatment modalities
for SSRI and SNRI antidepressants in Italy during the period 2003-2009. Curr Med Res
Opin. 2012 Jul 19.
19. Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M,Bianchini E, Medea
G, Cricelli C, Caputi AP, Mazzaglia G. Epidemiology of gout and hyperuricaemia in Italy
during the years 2005-2009: a nationwide population-based study.Ann Rheum Dis. 2012
Jun 26.
20. Valkhoff VE, van Soest EM, Mazzaglia G, Molokhia M, Schade R, Trifiro G,Goldstein JL,
Hernandez-Diaz S, Kuipers EJ, Sturkenboom MC. Adherence to gastroprotection during
cyclooxygenase 2 inhibitor treatment and therisk of upper gastrointestinal tract events: A
population-based study. Arthritis Rheum. 2012 Aug;64(8):2792-802.
21. Coloma PM, Trifirò G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Picelli
G, Corrao G, Pedersen L, van der Lei J, Sturkenboom M; EU-ADR Consortium. Electronic
healthcare databases for active drug safety surveillance: is there enough leverage? Phar-
macoepidemiol Drug Saf. 2012 Jun;21(6):611-21.
22. Trifirò G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, Herings R,
de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini
R, Sturkenboom MC. Risk of cardiac valve regurgitation with dopamine agonist use in
Parkinson’s disease and hyperprolactinaemia: a multi-country, nested case-control study.
Drug Saf. 2012 Feb 1;35(2):159-71.
23. Mokhles MM, Trifirò G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM,Mazzaglia
G, Herings R, Luise Cd, Ross D, Brusselle G, Colao A, Haverkamp W,Schade R, Camp Gv,
Zanettini R, Sturkenboom MC. The risk of new onset heart failure associated with dopa-
mine agonist use in Parkinson’s disease. PharmacolRes. 2012 Mar;65(3):358-64.
24. Lapi F, Simonetti M, Michieli R, Pasqua A, Brandi ML, Frediani B, Cricelli C, Mazzaglia G.
Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary
care. Bone. 2012 Jan;50(1):85-90.
